Interim Guidelines on Antiviral Therapy for COVID-19

키워드

참고문헌 (131)

1. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
2. Jin Yong Kim, "The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures", Journal of Korean Medical Science, 35(5), pp.1~4 (2020), 대한의학회[DOI]
3. "Coronavirus disease-19, Republic of Korea"[URL]
4. Lu R, "Genomic characterisation and epidemiology of 2019 novel coronavirus : implications for virus origins and receptor binding", Lancet, 395, pp.565~574 (2020)
5. Li Q, "Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia", N Engl J Med, 382, pp.1199~1207 (2020)
6. Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China : a descriptive study", Lancet, 395, pp.507~513 (2020)
7. Wang D, "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China", JAMA, 323, pp.1061~1069 (2020)
8. Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
9. Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", JAMA (2020)
10. Korean Society of Infectious Diseases, "Report on the Epidemiological Features of Coronavirus Disease 2019 (COVID-19) Outbreak in the Republic of Korea from January 19 to March 2, 2020", Journal of Korean Medical Science, 35(10), pp.1~11 (2020), 대한의학회[DOI]
11. "Severe outcomes among patients with coronavirus disease 2019 (COVID-19) — United States, February 12–March 16, 2020"[URL]
12. "Coronavirus diseases 19"[URL]
13. "The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) - China" (2020)[URL]
14. Korean Society of Infectious Diseases, "Analysis on 54 Mortality Cases of Coronavirus Disease 2019 in the Republic of Korea from January 19 to March 10, 2020", Journal of Korean Medical Science, 35(12), pp.1~9 (2020), 대한의학회[DOI]
15. Peiris JSM, "Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study", Lancet, 361, pp.1767~1772 (2003)
16. Stockman LJ, "SARS : systematic review of treatment effects", PLoS Med, 3, pp.e343~ (2006)
17. Treanor JJ, "Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza : a randomized controlled trial", JAMA, 283, pp.1016~1024 (2000)
18. Liu Y, "Viral dynamics in mild and severe cases of COVID-19", Lancet Infect Dis, 20, pp.656~657 (2020)
19. Granados A, "Influenza and rhinovirus viral load and disease severity in upper respiratory tract infections", J Clin Virol, 86, pp.14~19 (2017)
20. Hijano DR, "Clinical correlation of influenza and respiratory syncytial virus load measured by digital PCR", PLoS One, 14, pp.e0220908~ (2019)
21. Hung IFN, "Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial", Lancet, 395, pp.1695~1704 (2020)
22. Momattin H, "A Systematic review of therapeutic agents for the treatment of the Middle East respiratory syndrome coronavirus(MERS-CoV)", Travel Med Infect Dis, 30, pp.9~18 (2019)
23. Dong L, "Discovering drugs to treat coronavirus disease 2019(COVID-19)", Drug Discov Ther, 14, pp.58~60 (2020)
24. Best BM, "Pharmacokinetics of lopinavir", ritonavir crushed versus whole tablets in children, 2011, pp.58, 385~391
25. Arabi YM, "Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b(MIRACLE trial) : study protocol for a randomized controlled trial", Trials, 19, pp.81~ (2018)
26. Xie J, "Critical care crisis and some recommendations during the COVID-19 epidemic in China", Intensive Care Med, 46, pp.837~840 (2020)
27. Cai Q, "Experimental treatment with favipiravir for COVID-19: an open-label control study", Engineering (2020)
28. Vincent MJ, "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread", Virol J, 2, pp.69~ (2005)
29. Keyaerts E, "In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine", Biochem Biophys Res Commun, 323, pp.264~268 (2004)
30. Barnard DL, "Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB", c mice, 2006, pp.17, 275~284
31. Dyall J, "Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection", Antimicrob Agents Chemother, 58, pp.4885~4893 (2014)
32. de Wilde AH, "Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture", Antimicrob Agents Chemother, 58, pp.4875~4884 (2014)
33. Keyaerts E, "Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice", Antimicrob Agents Chemother, 53, pp.3416~3421 (2009)
34. Thomé R, "Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis", PLoS One, 8, pp.e65913~ (2013)
35. Cong Y, "MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells", PLoS One, 13, pp.e0194868~ (2018)
36. Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro", Cell Res, 30, pp.269~271 (2020)
37. Gao J, "Breakthrough : Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies", Biosci Trends, 14, pp.72~73 (2020)
38. Multicenter collaboration group of Department of Science, "Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia", Zhonghua Jie He He Hu Xi Za Zhi, 43, pp.185~188 (2020)
39. Biot C, "Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities", J Med Chem, 49, pp.2845~2849 (2006)
40. McChesney EW, "Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate", Am J Med, 75(1A), pp.11~18 (1983)
41. Liu J, "Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro", Cell Discov, 6, pp.16~ (2020)
42. Yao X, "In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)", Clin Infect Dis (2020)
43. Chen Z, "Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial", medRxiv, ~ (2020)
44. Chen J, "A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19", Zhejiang Da Xue Xue Bao Yi Xue Ban, 49, pp.215~219 (2020)
45. Tang W, "Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial", medRxiv, ~ (2020)
46. Gautret P, "Hydroxychloroquine and azithromycin as a treatment of COVID-19 : results of an open-label non-randomized clinical trial", Int J Antimicrob Agents, pp.105949~ (2020)
47. Molina JM, "No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection", Med Mal Infect, 50, pp.384~ (2020)
48. Weniger H, "Review of side effects and toxicity of chloroquine", WHO, ~ (1979)
49. Chen F, "In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds", J Clin Virol, 31, pp.69~75 (2004)
50. López Aspiroz E, "Population pharmacokinetics of lopinavir", ritonavir(Kaletra)in HIV-infected patients, 2011, pp.33, 573~582
51. Liu X, "Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines", J Genet Genomics, 47, pp.119~121 (2020)
52. Chan JFW, "Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus", J Infect, 67, pp.606~616 (2013)
53. Chan JFW, "Treatment with lopinavir", ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset, 2015, pp.212, 1904~1913
54. Chan KS, "Treatment of severe acute respiratory syndrome with lopinavir", ritonavir : a multicentre retrospective matched cohort study, 2003, pp.9, 399~406
55. Chu CM, "Role of lopinavir", ritonavir in the treatment of SARS : initial virological and clinical findings, 2004, pp.59, 252~256
56. Spanakis N, "Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen", Int J Antimicrob Agents, 44, pp.528~532 (2014)
57. Kim UJ, "Combination therapy with lopinavir", ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome, 2016, pp.21, 455~459
58. 최원석, "Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea", Infection and Chemotherapy, 48(2), pp.118~126 (2016), 대한감염학회
59. Cao B, "A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19", N Engl J Med, 382, pp.1787~1799 (2020)
60. Dahl H, "In vitro inhibition of SARS virus replication by human interferons", Scand J Infect Dis, 36, pp.829~831 (2004)
61. Tan ELC, "Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs", Emerg Infect Dis, 10, pp.581~586 (2004)
62. de Wilde AH, "MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment", J Gen Virol, 94, pp.1749~1760 (2013)
63. Lee AJ, "The dual nature of type I and type II interferons", Front Immunol, 9, pp.2061~ (2018)
64. Teijaro JR, "Persistent LCMV infection is controlled by blockade of type I interferon signaling", Science, 340, pp.207~211 (2013)
65. Stock AT, "Type I IFN suppresses Cxcr2 driven neutrophil recruitment into the sensory ganglia during viral infection", J Exp Med, 211, pp.751~759 (2014)
66. Brown AJ, "Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase", Antiviral Res, 169, pp.104541~ (2019)
67. adenine C-nucleoside(GS-5734)for the treatment of Ebola and emerging viruses, "J Med Chem", 2017, 1648~1661
68. Warren TK, "Therapeutic efficacy of the small molecule GS- 5734 against Ebola virus in rhesus monkeys", Nature, 531, pp.381~385 (2016)
69. Sheahan TP, "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses", Sci Transl Med, 9, pp.eaal3653~ (2017)
70. de Wit E, "Prophylactic and therapeutic remdesivir(GS-5734)treatment in the rhesus macaque model of MERS-CoV infection", Proc Natl Acad Sci U S A, 117, pp.6771~6776 (2020)
71. Dörnemann J, "First newborn baby to receive experimental therapies survives Ebola virus disease", J Infect Dis, 215, pp.171~174 (2017)
72. Mulangu S, "A Randomized, controlled trial of Ebola virus disease therapeutics", N Engl J Med, 381, pp.2293~2303 (2019)
73. Holshue ML, "Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States", N Engl J Med, 382, pp.929~936 (2020)
74. Grein J, "Compassionate use of remdesivir for patients with severe Covid-19", N Engl J Med, 382, pp.2327~2336 (2020)
75. "Clinical trials for remdesivir in COVID-19"[URL]
76. Shiraki K, "Favipiravir, an anti-influenza drug against life-threatening RNA virus infections", Pharmacol Ther, pp.107512~ (2020)
77. Furuta Y, "Favipiravir(T-705), a novel viral RNA polymerase inhibitor", Antiviral Res, 100, pp.446~454 (2013)
78. Oestereich L, "Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever", PLoS Negl Trop Dis, 8, pp.e2804~ (2014)
79. Morrey JD, "Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents", Antiviral Res, 80, pp.377~379 (2008)
80. Delang L, "Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir(T-705), a broad-spectrum antiviral", J Antimicrob Chemother, 69, pp.2770~2784 (2014)
81. Sissoko D, "Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea", PLoS Med, 13, pp.e1001967~ (2016)
82. Bai CQ, "Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir(T-705)-Sierra Leone, 2014", Clin Infect Dis, 63, pp.1288~1294 (2016)
83. Chen C, "Favipiravir versus Arbidol for COVID-19: a randomized clinical trial", medRxiv, ~ (2020)
84. Ströher U, "Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α", J Infect Dis, 189, pp.1164~1167 (2004)
85. Lau EH, "Effectiveness of ribavirin and corticosteroids for severe acute respiratory syndrome", Am J Med, 122, pp.1150.e11~1150.e21 (2009)
86. Poutanen SM, "Identification of severe acute respiratory syndrome in Canada", N Engl J Med, 348, pp.1995~2005 (2003)
87. Tsang KW, "A cluster of cases of severe acute respiratory syndrome in Hong Kong", N Engl J Med, 348, pp.1977~1985 (2003)
88. Booth CM, "Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area", JAMA, 289, pp.2801~2809 (2003)
89. Hsu LY, "Severe acute respiratory syndrome(SARS)in Singapore : clinical features of index patient and initial contacts", Emerg Infect Dis, 9, pp.713~717 (2003)
90. Zhao Z, "Description and clinical treatment of an early outbreak of severe acute respiratory syndrome(SARS)in Guangzhou, PR China", J Med Microbiol, 52, pp.715~720 (2003)
91. Sung JJY, "Severe acute respiratory syndrome : report of treatment and outcome after a major outbreak", Thorax, 59, pp.414~420 (2004)
92. Leong HN, "Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003", Trop Med Int Health, 9, pp.923~927 (2004)
93. Morgenstern B, "Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines", Biochem Biophys Res Commun, 326, pp.905~908 (2005)
94. Chen F, "In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds", J Clin Virol, 31, pp.69~75 (2004)
95. Falzarano D, "Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques", Nat Med, 19, pp.1313~1317 (2013)
96. Chiou HE, "Adverse effects of ribavirin and outcome in severe acute respiratory syndrome : experience in two medical centers", Chest, 128, pp.263~272 (2005)
97. Knowles SR, "Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada", Clin Infect Dis, 37, pp.1139~1142 (2003)
98. Omrani AS, "Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection : a retrospective cohort study", Lancet Infect Dis, 14, pp.1090~1095 (2014)
99. Shalhoub S, "IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia : a retrospective study", J Antimicrob Chemother, 70, pp.2129~2132 (2015)
100. Momattin H, "Therapeutic options for Middle East respiratory syndrome coronavirus(MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy", Int J Infect Dis, 17, pp.e792~e798 (2013)
101. Cheng VCC, "Clinical management and infection control of SARS : lessons learned", Antiviral Res, 100, pp.407~419 (2013)
102. Liu F, "Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression", Int J Infect Dis, 95, pp.183~191 (2020)
103. Deng L, "Arbidol combined with LPV", r versus LPV, J Infect, pp.2020, 81[DOI]
104. Jin YH, "A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019- nCoV) infected pneumonia (standard version)", Mil Med Res, 7, pp.4~ (2020)
105. Cortegiani A, "A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19", J Crit Care, 57, pp.279~283 (2020)
106. Belhadi D, "A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19", medRxiv, ~ (2020)
107. Stockman LJ, "SARS : systematic review of treatment effects", PLoS Med, 3, pp.e343~ (2006)
108. Arabi YM, "Corticosteroid therapy for critically Ill patients with Middle East respiratory syndrome", Am J Respir Crit Care Med, 197, pp.757~767 (2018)
109. Rochwerg B, "Corticosteroids in sepsis : an updated systematic review and meta-analysis", Crit Care Med, 46, pp.1411~1420 (2018)
110. Lian XJ, "Reevaluating the Role of Corticosteroids in Septic Shock : An Updated Meta-Analysis of Randomized Controlled Trials", BioMed Res Int, 2019, pp.3175047~ (2019)
111. Siemieniuk RA, "Corticosteroid therapy for patients hospitalized with community-acquired pneumonia : a systematic review and meta-analysis", Ann Intern Med, 163, pp.519~528 (2015)
112. Villar J, "Dexamethasone treatment for the acute respiratory distress syndrome : a multicentre, randomised controlled trial", Lancet Respir Med, 8, pp.267~276 (2020)
113. Lewis SR, "Pharmacological agents for adults with acute respiratory distress syndrome", Cochrane Database Syst Rev, 7, pp.CD004477~ (2019)
114. Wang Y, "low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China", medRxiv, ~ (2020)
115. Wu C, "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China", JAMA Intern Med, pp.e200994~ (2020)
116. World Health Organization (WHO), "Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020", WHO, ~ (2020)
117. Russell CD, "Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury", Lancet, 395, pp.473~475 (2020)
118. Villar J, "Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome : study protocol for a randomized controlled trial", Trials, 17, pp.342~ (2016)
119. Lamontagne F, "Corticosteroid therapy for sepsis: a clinical practice guideline", BMJ, 362, pp.k3284~ (2018)
120. Ho JC, "Pentaglobin in steroid-resistant severe acute respiratory syndrome", Int J Tuberc Lung Dis, 8, pp.1173~1179 (2004)
121. Lew TW, "Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome", JAMA, 290, pp.374~380 (2003)
122. Lu H, "Drug treatment options for the 2019-new coronavirus(2019-nCoV)", Biosci Trends, 14, pp.69~71 (2020)
123. Yang X, "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China : a single-centered, retrospective, observational study", Lancet Respir Med, 8, pp.475~481 (2020)
124. Soo YO, "Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients", Clin Microbiol Infect, 10, pp.676~678 (2004)
125. Yeh KM, "Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital", J Antimicrob Chemother, 56, pp.919~922 (2005)
126. Cheng Y, "Use of convalescent plasma therapy in SARS patients in Hong Kong", Eur J Clin Microbiol Infect Dis, 24, pp.44~46 (2005)
127. Mair-Jenkins J, "The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology : a systematic review and exploratory meta-analysis", J Infect Dis, 211, pp.80~90 (2015)
128. Shen C, "Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma", JAMA, 323, pp.1582~1589 (2020)
129. 안진영, "Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea", Journal of Korean Medical Science, 35(14), pp.1~8 (2020), 대한의학회[DOI]
130. Choe PG, "MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015", Emerg Infect Dis, 23, pp.1079~1084 (2017)
131. Ko JH, "Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection : a single centre experience", Antivir Ther, 23, pp.617~622 (2018)

관련 논문AI추천